These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 7549671)

  • 1. Informed consent to postmarketing research. British rules outlaw disguised promotion of drugs.
    Wells F
    BMJ; 1995 Sep; 311(7006):692. PubMed ID: 7549671
    [No Abstract]   [Full Text] [Related]  

  • 2. Financial ties as part of informed consent to postmarketing research. Attitudes of American doctors and patients.
    La Puma J; Stocking CB; Rhoades WD; Darling CM; Ferner RE; Neuberger J; VandenBurg M; Dews I; Tobias JS
    BMJ; 1995 Jun; 310(6995):1660-3. PubMed ID: 7795459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global harmonization is not all that global: divergent approaches in drug safety.
    Castle GH; Kelly B
    Food Drug Law J; 2008; 63(3):601-22. PubMed ID: 19031662
    [No Abstract]   [Full Text] [Related]  

  • 4. Secrecy and product liability litigation.
    Brahams D
    Lancet; 1990 Sep; 336(8717):737-8. PubMed ID: 1975905
    [No Abstract]   [Full Text] [Related]  

  • 5. Issues for research ethics committees: third installment.
    Evans D; Crossland N; Graham I; Preece A
    Bull Med Ethics; 1998 Feb; No. 135():13-6. PubMed ID: 11657246
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug companies cut costs with foreign clinical trials.
    Rai S
    N Y Times Web; 2005 Feb; ():C4. PubMed ID: 15742516
    [No Abstract]   [Full Text] [Related]  

  • 7. Highly lauded drug assessment program under attack.
    Silversides A
    CMAJ; 2008 Jul; 179(1):26-7. PubMed ID: 18509096
    [No Abstract]   [Full Text] [Related]  

  • 8. Promotion of medicines.
    Massam D
    Lancet; 1989 Jun; 1(8650):1330. PubMed ID: 2566856
    [No Abstract]   [Full Text] [Related]  

  • 9. Research ethics review in Australia, Europe and North America.
    McNeill PM
    IRB; 1989; 11(3):4-7. PubMed ID: 11650207
    [No Abstract]   [Full Text] [Related]  

  • 10. Reviewing research involving children: the practice of British research ethics committees.
    Hall D
    IRB; 1988; 10(2):1-5. PubMed ID: 11650021
    [No Abstract]   [Full Text] [Related]  

  • 11. Divide and rule.
    Nicholson RH
    IRB; 1992; 14(4):10-1. PubMed ID: 11651392
    [No Abstract]   [Full Text] [Related]  

  • 12. New rules for new drugs: the challenge of AIDS to the regulatory process.
    Edgar H; Rothman DJ
    Milbank Q; 1990; 68(Suppl. 1):111-42. PubMed ID: 11650413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Industry reneges on postmarketing trial commitments.
    Bouchie A
    Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074
    [No Abstract]   [Full Text] [Related]  

  • 14. Get informed consent for risky drugs.
    Johnson LJ
    Med Econ; 2007 Nov; 84(21):20. PubMed ID: 18074929
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 16. Ethics of volunteer research: the role of new EC guidelines.
    Haynes WG; Webb DJ
    Br J Clin Pharmacol; 1991 Dec; 32(6):671-6. PubMed ID: 1768558
    [No Abstract]   [Full Text] [Related]  

  • 17. More research guidelines for comment.
    ;
    Bull Med Ethics; 2001 Apr; (167):13-9. PubMed ID: 11878339
    [No Abstract]   [Full Text] [Related]  

  • 18. [Sense and nonsense of post-authorization surveillance].
    de Mey C
    Med Klin (Munich); 2000 Jan; 95(1):56-62. PubMed ID: 10668347
    [No Abstract]   [Full Text] [Related]  

  • 19. Informed consent and approval by institutional review boards in published reports on clinical trials.
    Ruiz-Canela M; Martínez-González MA; Gómez-Gracia E; Fernández-Crehuet J
    N Engl J Med; 1999 Apr; 340(14):1114-5. PubMed ID: 10206829
    [No Abstract]   [Full Text] [Related]  

  • 20. Lessons from Eprex for biogeneric firms.
    Louët S
    Nat Biotechnol; 2003 Sep; 21(9):956-7. PubMed ID: 12949539
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.